Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators. Luke JJ, et al. Among authors: mackiewicz j. Lancet. 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. Lancet. 2022. PMID: 35367007 Clinical Trial.
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Ribas A, et al. Among authors: mackiewicz j. J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7. J Clin Oncol. 2013. PMID: 23295794 Free PMC article. Clinical Trial.
Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma.
O'Day SJ, Eggermont AM, Chiarion-Sileni V, Kefford R, Grob JJ, Mortier L, Robert C, Schachter J, Testori A, Mackiewicz J, Friedlander P, Garbe C, Ugurel S, Collichio F, Guo W, Lufkin J, Bahcall S, Vukovic V, Hauschild A. O'Day SJ, et al. Among authors: mackiewicz j. J Clin Oncol. 2013 Mar 20;31(9):1211-8. doi: 10.1200/JCO.2012.44.5585. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401447 Clinical Trial.
Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis.
Wiater K, Switaj T, Mackiewicz J, Kalinka-Warzocha E, Wojtukiewicz M, Szambora P, Falkowski S, Rogowski W, Mackiewicz A, Rutkowski P. Wiater K, et al. Among authors: mackiewicz a, mackiewicz j. Contemp Oncol (Pozn). 2013;17(3):257-62. doi: 10.5114/wo.2013.35785. Epub 2013 Jun 28. Contemp Oncol (Pozn). 2013. PMID: 24596511 Free PMC article.
The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial.
Rutkowski P, Kozak K, Mackiewicz J, Krzemieniecki K, Nawrocki S, Wasilewska-Teśluk E, Kwinta Ł, Wysocki P, Koseła-Paterczyk H, Świtaj T. Rutkowski P, et al. Among authors: mackiewicz j. Contemp Oncol (Pozn). 2015;19(4):280-3. doi: 10.5114/wo.2015.54082. Epub 2015 Sep 28. Contemp Oncol (Pozn). 2015. PMID: 26557775 Free PMC article.
High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
Teterycz P, Jagodzińska-Mucha P, Cybulska-Stopa B, Mariuk-Jarema A, Kozak K, Koseła-Paterczyk H, Czarnecka AM, Rajczykowski M, Dziura R, Galus Ł, Mackiewicz J, Świtaj T, Klimczak A, Falkowski S, Suwiński R, Ziobro M, Ługowska I, Rutkowski P. Teterycz P, et al. Among authors: mackiewicz j. Melanoma Res. 2018 Oct;28(5):435-441. doi: 10.1097/CMR.0000000000000461. Melanoma Res. 2018. PMID: 29782381
Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence.
Cybulska-Stopa B, Rogala P, Czarnecka AM, Ługowska I, Teterycz P, Galus Ł, Rajczykowski M, Dawidowska A, Piejko K, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Among authors: mackiewicz j. Adv Med Sci. 2020 Sep;65(2):316-323. doi: 10.1016/j.advms.2020.05.005. Epub 2020 Jun 15. Adv Med Sci. 2020. PMID: 32554313
Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.
Cybulska-Stopa B, Ziętek M, Kamińska-Winciorek G, Czarnecka AM, Piejko K, Galus Ł, Ziółkowska B, Kieszko S, Kempa-Kamińska N, Calik J, Zemełka T, Kubiatowski T, Suwiński R, Mackiewicz J, Rutkowski P. Cybulska-Stopa B, et al. Among authors: mackiewicz j. Melanoma Res. 2021 Feb 1;31(1):49-57. doi: 10.1097/CMR.0000000000000705. Melanoma Res. 2021. PMID: 33165240
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Kelly RJ, et al. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. N Engl J Med. 2021. PMID: 33789008 Clinical Trial.
232 results